文献速递产科母胎医学

将游离DNA筛查引入临床实践对早孕期超声的影响

Impact of introducing cell-free DNA screening into clinical care on first trimester ultrasound.
PubMed 文献 · Prenat Diagn · 2022-01-10

这项回顾性研究比较了三种非整倍体筛查方案下早孕期超声的执行情况。结果显示,当要求患者在联合早孕期筛查与游离DNA之间二选一时,接受早孕期超声的比例从68.7%降至40.9%,颈项透明层扫描从6.8%降至1.3%。

要点

  • 将cfDNA作为FTS的替代方案后,接受早孕期超声的患者比例下降。
  • 方案三中早孕期超声比例40.9% vs 方案二68.7%(OR 0.32,95%CI 0.25-0.4,p<0.001)。
  • 方案二至方案三NT扫描从6.8%降至1.3%(OR 0.18,95%CI 0.09-0.4,p<0.001)。

核心结论

  • 将cfDNA筛查作为FTS的替代方案,导致接受早孕期超声的患者减少。

研究设计与样本

  • 回顾性研究,纳入在一家三级转诊中心接受产前保健的患者,比较研究期间连续使用的三种非整倍体筛查方案。

主要发现

  • 方案二下早孕期超声数量与方案一相似,但方案三下下降(68.7% vs 40.9%,OR 0.32,95%CI 0.25-0.4,p<0.001)。
  • 诊断性操作从方案一的7.6%降至方案二的4.4%(OR 0.59,95%CI 0.37-0.93,p=0.02)。
  • NT扫描从方案二的6.8%降至方案三的1.3%(OR 0.18,95%CI 0.09-0.4,p<0.001)。
  • 研究期间FTS率下降,且当患者必须二选一时接受cfDNA的女性更少(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: First-trimester ultrasound is an important component of prenatal care. We investigated the impact of introducing cell-free DNA (cfDNA) aneuploidy screening into routine care, on performance of first-trimester ultrasound. METHODS: Retrospective study of patients who had prenatal care at a tertiary referral center. We compared the performance of any first-trimester ultrasound between three different aneuploidy screening protocols, used consecutively during the study period: (1) combined first-trimester screening (FTS); (2) FTS and cfDNA offered together; (3) patients requested to choose between FTS and cfDNA. Secondary outcomes included performance of nuchal translucency (NT), aneuploidy screens and diagnostic genetic procedures. RESULTS: The number of patients undergoing first-trimester ultrasound remained similar with the second protocol but decreased in the third (68.7% vs. 40.9%, OR 0.32, 95% CI 0.25-0.4, p < 0.001). Diagnostic procedures decreased between protocol 1 and 2 (7.6% vs. 4.4%, OR 0.59, 95% CI 0.37-0.93, p = 0.02) while NT scans decreased between protocol 2 and 3 (6.8% vs. 1.3%, OR 0.18, 95% CI 0.09-0.4, p < 0.001). The rate of FTS decreased over the study period and less women had cfDNA when they had to choose one method (p < 0.001). CONCLUSIONS: Introducing cfDNA screening as an alternative to FTS, resulted in fewer patients receiving ultrasound in the first-trimester.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Doulaveris G, Igel CM, Estrada Trejo F, et al. Impact of introducing cell-free DNA screening into clinical care on first trimester ultrasound. Prenat Diagn. 2022. PMID: 34989002. doi:10.1002/pd.6086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。